Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative treatments for addiction and related disorders. Founded in 2014, Opiant has made significant strides in the industry, particularly with its flagship product, Narcan® (naloxone), which is pivotal in reversing opioid overdoses. With a focus on addressing the urgent needs of patients and healthcare providers, Opiant's unique approach combines advanced science with a commitment to public health. The company operates primarily in the US but is also expanding its reach into international markets. Recognised for its contributions to combating the opioid crisis, Opiant continues to solidify its position as a key player in the biopharmaceutical sector, striving to improve lives through effective and accessible treatment solutions.
DitchCarbon Score
How does Opiant Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Opiant Pharmaceuticals, Inc.'s score of 37 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Opiant Pharmaceuticals, Inc.'s reported carbon emissions
In 2023, Opiant Pharmaceuticals, Inc. reported total carbon emissions of approximately 113,000,000 kg CO2e. This figure includes 4,573,000 kg CO2e from Scope 1 emissions, 2,366,000 kg CO2e from Scope 2 emissions (market-based), and a significant 107,779,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (66,927,000 kg CO2e) and downstream transportation and distribution (19,855,000 kg CO2e). Comparatively, in 2022, the company recorded 3,433,000 kg CO2e in Scope 1 and 1,874,000 kg CO2e in Scope 2 emissions, indicating a rise in emissions across all scopes in 2023. The 2021 data shows similar trends, with Scope 1 emissions at 2,428,000 kg CO2e and Scope 2 emissions at 2,073,000 kg CO2e. Opiant Pharmaceuticals has set ambitious climate commitments, aiming for a 100% transition to hybrid vehicles by the end of 2026, which applies to both Scope 1 and Scope 2 emissions. This initiative reflects the company's near-term net-zero strategy, although specific overall reduction percentages have not been disclosed. The emissions data is not cascaded from any parent organisation, indicating that Opiant Pharmaceuticals, Inc. independently reports its carbon footprint and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,428,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,073,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Opiant Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
